Digital Health Strategy Monitor
Bi-weekly Digital Health market development news.
Edition 04 - Covering Mar 10 - Mar 23, 2026
You can feel it in the data: digital health in 2026 is no longer about 'growth at all costs', but about clinically validated, AI-enabled solutions that are deeply embedded in workflows – on both sides of the Atlantic.
Between 10–23 March 2026 we've seen steady signals:
- Galen Growth's 2026 HT250 ranking (top 250 early-stage digital health startups globally) shows an investor focus on AI-native platforms.
- Extended Medicare telehealth flexibilities + upcoming CMS ACCESS model.
- And disciplined M&A building integrated virtual/chronic-care platforms.
I've put together a curated briefing covering these developments with a US + EU/DACH lens – investments, reimbursement trends (DiGA, EHDS-context) and strategic consolidation. It's based entirely on public sources as a board-level starting point.
Click here for the full biweekly Digital Health Strategy Monitor in pdf.
My YTD 2026 conclusion: After a soft Q1 with funding down 35% YoY, March shows increasing M&A discipline (Talkspace, Eucalyptus, Kaia) and clearer reimbursement paths (ACCESS, DiGA 2.0). Investors reward workflow integrated, clinically validated and payer-aligned solutions. The consolidation wave has truly begun?" I would love to hear your opinion.
Edition 03 - Covering Feb 24 - Mar 9, 2026
Digital health is shifting from apps to infrastructure.
Key developments in the past two weeks (Feb 23 – Mar 9 2026):
• Digital therapeutics funding:
nyra health raised €20M to scale AI-based neurotherapy for stroke and dementia care.
• Health-tech venture funding:
Sage ($65M) and UnityAI ($8.5M) raised capital for senior care technology and AI-driven health analytics.
• AI in clinical trials:
AstraZeneca’s digital health platform Evinova signed agreements with multiple pharma companies to deploy AI-driven trial design tools.
• Axena Health Leva study:
Leva Digital Therapeutic Pelvic Health System improves fecal incontinence symptoms in real-world patient cohort.
• Remote monitoring innovation:
The FDA just changes the future of wearables. Check it out.
And, new wearable solutions such as smart fall-prevention insoles show continued expansion of digital care devices.
My strategic takeaway:
The momentum of the past two weeks shows healthcare moving decisively toward AI‑powered, remote, and patient‑centric models.
Click here for the full biweekly Digital Health Strategy Monitor in pdf. (Document includes sources.)
#DigitalHealth # MedTech #Biweekly #News #Monitor #Investments #Reimburserment
Sources:
EU-Startups, Fierce Healthcare, DigitalHealth.net, LucidQuest Ventures, Axena Health, FDA (Feb–Mar 2026)
Edition 02 - Covering Feb 9 - 23, 2026
Digital health is evolving from experimentation to reimbursable, globally scalable care.
In the past two weeks (Feb 9–23, 2026), key developments include:
Funding & Reimbursable DTx: Big Health raised ~$23.7 M to expand FDA-cleared, reimbursable digital mental health treatments (SleepioRx & DaylightRx). Capital clearly follows clinical validation and payer alignment.¹
Platform + AI Integration: Wellgistics Health invested in a mental health AI startup, integrating digital therapeutics with pharmacy and adherence solutions.²
Global Platform Consolidation: Hims & Hers acquired Eucalyptus for ~$1.15 B, expanding cross-border telehealth capabilities.³
Reimbursement Signals: Medicare/Medicaid pilots for AI-enabled utilization management, private payer alignment, and VA integration indicate that reimbursement and coverage governance are key for adoption.⁴
Strategic takeaway: Design for reimbursement, clinical evidence, and integrated workflows — that’s where value scales in digital health.
Click here for the full biweekly Digital Health Strategy Monitor in pdf.
#DigitalHealth # MedTech #Biweekly #News #Monitor #Investments #Reimburserment
Sources:
¹ Big Health funding & reimbursable DTx (Feb 12, 2026) ² Wellgistics Health investment in mental health AI (Feb 18, 2026) ³ Hims & Hers / Eucalyptus acquisition (Feb 19, 2026) ⁴ US payer policy dynamics including AI pilot and Medicare/Medicaid updates (Feb 15, 2026)
Edition 01 - Covering Jan 28 - Feb 8, 2026
Digital health has crossed a critical threshold — from concept to strategically measurable clinical and commercial impact.
Over the past 14 days, capital continued to flow into both reimbursable therapeutic platforms and payer-aligned AI infrastructure, with a new $425M Fund IV focused on early-stage digital care and a $16M Series A for AI-powered payer support.^1,2
FDA signalled a new era for digital health regulation, launching the TEMPO pilot in partnership with CMS to promote outcome-aligned access, and installing an AI-centric leader at its Digital Health Center of Excellence.^3,4
Reimbursement realities remain dynamic — temporary shifts in Medicare telehealth flexibilities highlight ongoing payer negotiations and the evolving bounds of virtual care coverage.^5
The path forward in digital health is getting paved by clinical credibility, reimbursement alignment, and outcome-oriented product strategy — not just innovation for its own sake.
Click here for the full biweekly Digital Health Strategy Monitor in pdf.
#DigitalHealth #AI #Reimbursement #Medicare #Telehealth #VC #HealthTech
Sources:
1) Frist Cressey Ventures Fund IV, Feb 19 2026; 2) Daffodil Health Series A, Feb 17 2026; 3) FDA TEMPO Pilot, Feb 3 2026; 4) FDA Digital Health Center leadership, Feb 19 2026; 5) Medicare telehealth policy, Feb 2026
Edition 01 - Covering Jan 28 - Feb 8, 2026
Digital health has crossed a critical threshold — from concept to strategically measurable clinical and commercial impact.
Over the past 14 days, capital continued to flow into both reimbursable therapeutic platforms and payer-aligned AI infrastructure, with a new $425M Fund IV focused on early-stage digital care and a $16M Series A for AI-powered payer support.^1,2
FDA signalled a new era for digital health regulation, launching the TEMPO pilot in partnership with CMS to promote outcome-aligned access, and installing an AI-centric leader at its Digital Health Center of Excellence.^3,4
Reimbursement realities remain dynamic — temporary shifts in Medicare telehealth flexibilities highlight ongoing payer negotiations and the evolving bounds of virtual care coverage.^5
The path forward in digital health is getting paved by clinical credibility, reimbursement alignment, and outcome-oriented product strategy — not just innovation for its own sake.
Click here for the full biweekly Digital Health Strategy Monitor in pdf.
#DigitalHealth #AI #Reimbursement #Medicare #Telehealth #VC #HealthTech
Sources:
1) Frist Cressey Ventures Fund IV, Feb 19 2026; 2) Daffodil Health Series A, Feb 17 2026; 3) FDA TEMPO Pilot, Feb 3 2026; 4) FDA Digital Health Center leadership, Feb 19 2026; 5) Medicare telehealth policy, Feb 2026